Since early August, the world’s most valuable pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), has put on a stellar performance. After tanking 14% on Aug. 7 due to poor clinical trial results,

Eli Lilly has quietly turned a blockbuster obesity and diabetes franchise into one of the market's most intriguing income stories. The company's rapid growth, aggressive capital returns, and accelerating dividend policy are reshaping how I view big pharma in 2026,

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study. And through the first nine months of 2025, Zepbound generated $9.3 billion in revenue. Wegovy generated approximately $9 billion -- despite having been approved in the U.S. more than two years before its competitor.

As the oral GLP-1 race intensifies, Eli Lilly has slimmed back the number of phase 2 trials it is conducting for one of its contenders. The Big Pharma had been running three midstage studies of the GLP-1 drug, called naperiglipron, but the company ...

Indiana University’s Lilly Library is set to receive a large grant to enhance public understanding of the role religion plays in public life.

Alpha Wealth Funds, LLC, an investment management company, released its Q3 2025 letter for the “Insiders Fund”. A copy of the letter can be downloaded here. The fund returned 4.96% in September, bringing the YTD returns to 21.

Social media users can’t stop talking about a new Eli Lilly and Company commercial that some believe promotes obesity, while others argue that it instead encourages positive body image. The ad, titled “My Business,

Eli Lilly is considering all these risks and planning accordingly, and doing so years in advance. That's also why the pharmaceutical giant has been making a push in oncology. And why it is building an artificial intelligence supercomputer that could help it develop medicines much faster and at lower costs.